As internationalization gradually becomes the mainstream trend of development for China's biopharmaceutical industry, enterprises have intensified their efforts to go global, and the exchanges between the Chinese pharmaceutical....

Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized on June 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years.

Recently, Kexing Biopharm (688136.SH) has completed the first dose of its long-acting GC product, Pegylated Human Granulocyte Colony-stimulating Factor Injection (hereinafter referred to as long-acting GC) developed in China, in all enrolled subjects in Phase I clinical study, showing favorable safety and tolerability.

The 88th API China, a prestigious pharmaceutical event, took place at the Qingdao Cosmopolitan Exposition Exhibition Centre, where regional representatives from Kexing Biopharm's Overseas Marketing Division convened to participate.

Recently, Kexing Biopharm (688136.SH) signed with Chia-Tai Tianqing (CTTQ) an exclusive cooperation agreement for overseas commercialization of Trastuzumab for Injection recently. As a result, it has obtained the rights to commercialize the first batch of Trastuzumab for Injection in 12 countries.

Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm) has embarked on rebranding for distinction since 2019. Driven and directed by its mission of "precise products, predictable effects and health protection", Kexing Biopharm has worked to upgrade

Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm) has embarked on rebranding for distinction since 2019. Driven and directed by its mission of "precise products, predictable effects and health protection", Kexing Biopharm has worked to upgrade

On January 11, 2022, Kexing Biopharmaceutical Co., Ltd. (stock code: 688136.SH, hereinafter referred to as Kexing Biopharm) and TOT BIOPHARM (hereinafter referred to as Suzhou TOT BIOPHARM), a wholly-owned subsidiary of TOT BIOPHARM In